Antares Pharma, Inc. acquired by Halozyme Therapeutics

Halozyme Therapeutics agreed to acquire Antares Pharma, Inc., a life sciences / drug delivery technologies brand, on Apr 13, 2022.

Transaction summary

Target
Antares Pharma, Inc.
Seller
-
Announced
2022-04-13
Geography
-
Type
Acquisition
Deal type
Control
Stake acquired
-
First added
2026-06-19
Latest update
2026-10-21

Value and multiples

100% enterprise value

Undisclosed

Value not disclosed

Basis: FundComb estimate

Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.

EV / revenue

4.9x

Period not stated

Basis: FundComb estimate

EV / EBITDA

-

EBITDA basis not stated

Basis: FundComb estimate

Basis

  • The 4.9x revenue multiple comes from FundComb’s comps spreadsheet and is not confirmed by a public source; the price, revenue and period behind it are not stated. The Wall Street Journal reported on 13 April 2022 that Halozyme Therapeutics agreed to buy Antares Pharma.

Source summary

Halozyme Therapeutics Agrees to Buy Antares Pharma - WSJ

Confirmed
Open via Google News

Continue your research

Explore more comps →